A Phase 3 interventional study of Injectafer and Normal Saline in Cancer and Chemotherapy Related Anemia, sponsored by American Regent, Inc.. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.
This is a Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study. Subjects who meet all inclusion criteria and no exclusion criteria, will be randomized into the trial (Group A or B).
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 244 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
First submitted after American Regent, Inc. became part of Daiichi Sankyo.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
Drug: Injectafer
Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
Other: Normal Saline
Also known as: ferric carboxymaltose injection
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18
The following participants will be considered to have met the primary endpoint: * Participants with observed Hgb decrease from baseline between 0.5 g/dL to 1.0 g/dL on two consecutive visits between Weeks 3 and 18. * Participants with observed Hgb decrease from baseline ≥1.0 g/dL at one visit. * Participants who have a non-study intervention prior to Week 18. * Participants who discontinue prior to Week 18 for lack of efficacy or adverse events.
Time frame: Week 3 to Week 18
Change in Hemoglobin From Baseline to Week 18 or to Nonstudy Intervention
Nonstudy Intervention is defined as any of the following: * Initiation of erythropoietin for any reason * Blood transfusion * IV iron * Prescribed use of oral iron
Time frame: Baseline to Week 18
Percentage of Participants With Hemoglobin Increase From Baseline ≥ 1 g/dL at Any Postbaseline Visits Without Receiving a Nonstudy Intervention
Summary of number and percentage(%) of participants with Hgb increase ≥ 1 g/dL increase at any time point in the absence of non-study intervention.
Time frame: Baseline to Week 18
Percentage of Participants Who Received Nonstudy Intervention
Intervention is defined as any of the following: * Initiation of erythropoietin for any reason * Blood transfusion * IV iron * Prescribed use of oral iron
Time frame: Baseline to week 18
Percentage of Participants With Hemoglobin > 12 g/dL in the Absence of Non-study Intervention
Intervention is defined as any of the following: * Initiation of erythropoietin for any reason * Blood transfusion * IV iron * Prescribed use of oral iron
Time frame: Baseline to week 18
Time to Hemoglobin Increase ≥ 1 g/dL in the Absence of Non-study Intervention
Participants who discontinued or completed the study, or received a non-study intervention before having an increased in Hgb ≥ 1 g/dL will be censored at last study visit or time of receiving non-study intervention, respectively
Time frame: Baseline to Week 18
Percentage of Participants Requiring a Blood Transfusion
Summary of the number (percentage) of participants requiring a blood transfusion at any time during the trial.
Time frame: Baseline to week 18
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Day 7
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Week 2
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Week 3
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Week 6
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Week 9
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Week 12
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit.
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Week 15
Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
Time frame: Baseline to Week 18
Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18
Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.
Time frame: Baseline to Week 18
Time to a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Week 18
Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.
Time frame: From Baseline to Week 18
Correlation of Change in Hemoglobin With Baseline Hepcidin Level
For participants who receive non-study intervention or early withdraw from the study, the time of intervention or early withdrawal will be considered as end of study, respectively.
Time frame: Baseline to Week 18.
Total Score of the Functional Assessment of Chronic Illness Therapy Fatigue(FACIT-Fatigue) Scale Mean Change From Baseline to Week 18
Summary of the actual value and change from baseline in total score of Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue Scale). Ranges from 0-52 and higher scores mean better Quality of Life (QOL). Data collected after receiving non-study intervention will not be included in the summary.
Time frame: Baseline to Week 18
| Milestone | Injectafer | Normal Saline |
|---|---|---|
| Started | 122 | 122 |
| Completed | 81 | 82 |
| Not completed | 41 | 40 |
| Withdrew: Death | 15 | 13 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Lost to follow-up | 5 | 9 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 17 | 13 |
| Withdrew: Other reason | 1 | 4 |
The following participants will be considered to have met the primary endpoint: * Participants with observed Hgb decrease from baseline between 0.5 g/dL to 1.0 g/dL on two consecutive visits between Weeks 3 and 18. * Participants with observed Hgb decrease from baseline ≥1.0 g/dL at one visit. * Participants who have a non-study intervention prior to Week 18. * Participants who discontinue prior to Week 18 for lack of efficacy or adverse events.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18 | 42 | 60 |
Nonstudy Intervention is defined as any of the following: * Initiation of erythropoietin for any reason * Blood transfusion * IV iron * Prescribed use of oral iron
| g/dL | Injectafer | Normal Saline |
|---|---|---|
| Baseline | 9.63 ± 1.000 | 9.75 ± 1.008 |
| Day 7 Change from Baseline | 0.27 ± 0.901 | 0.01 ± 0.741 |
| Week 2 Change from Baseline | 0.53 ± 1.077 | 0.06 ± 0.937 |
| Week 3 Change from Baseline | 0.58 ± 1.015 | 0.04 ± 1.028 |
| Week 6 Change from Baseline | 0.84 ± 1.264 | 0.07 ± 1.254 |
| Week 9 Change from Baseline | 0.85 ± 1.174 | 0.37 ± 1.512 |
| Week 12 Change from Baseline | 1.00 ± 1.202 | 0.74 ± 1.274 |
| Week 15 Change from Baseline | 0.97 ± 1.394 | 0.79 ± 1.313 |
| Week 18/ET Change from Baseline | 1.04 ± 1.718 | 0.87 ± 1.475 |
Summary of number and percentage(%) of participants with Hgb increase ≥ 1 g/dL increase at any time point in the absence of non-study intervention.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With Hemoglobin Increase From Baseline ≥ 1 g/dL at Any Postbaseline Visits Without Receiving a Nonstudy Intervention | 84 | 64 |
Intervention is defined as any of the following: * Initiation of erythropoietin for any reason * Blood transfusion * IV iron * Prescribed use of oral iron
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants Who Received Nonstudy Intervention | 22 | 25 |
Intervention is defined as any of the following: * Initiation of erythropoietin for any reason * Blood transfusion * IV iron * Prescribed use of oral iron
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With Hemoglobin > 12 g/dL in the Absence of Non-study Intervention | 31 | 24 |
Participants who discontinued or completed the study, or received a non-study intervention before having an increased in Hgb ≥ 1 g/dL will be censored at last study visit or time of receiving non-study intervention, respectively
| Days | Injectafer | Normal Saline |
|---|---|---|
| Q1, 1st quartile | 15 (15 to 20) | 23 (21 to 43) |
| Q2, 2nd quartile or median | 43 (22 to 45) | 85 (64 to 106) |
| Q3, 3rd quartile | 106 (69 to NA) | NA (126 to NA) |
Summary of the number (percentage) of participants requiring a blood transfusion at any time during the trial.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants Requiring a Blood Transfusion | 15 | 14 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit | 18 | 29 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit | 17 | 28 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit | 12 | 33 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit | 12 | 32 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit | 9 | 21 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit. | 8 | 10 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit. | 8 | 12 |
Summary of the number and percentage(%) of participants with Hgb decrease (from baseline) ≥ 0.5 g/dL by visit.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Baseline to Each Study Visit | 12 | 9 |
Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.
| Days | Injectafer | Normal Saline |
|---|---|---|
| Q1 | 15 (14 to 43) | 14 (8 to 15) |
| Q2 | 127 (106 to NA) | 43 (22 to 64) |
Patients who discontinued or completed the study, or received a nonstudy intervention before having an increase in Hgb ≥ 0.5 g/dL were censored at last study visit or time of receiving nonstudy intervention, respectively.
| Days | Injectafer | Normal Saline |
|---|---|---|
| Q1,1st quartile | 15 (14 to 43) | 14 (8 to 15) |
| 2nd quartile or median | 127 (106 to NA) | 43 (22 to 64) |
| Q3, 3rd quartile | NA (NA to NA) | NA (128 to NA) |
For participants who receive non-study intervention or early withdraw from the study, the time of intervention or early withdrawal will be considered as end of study, respectively.
| g/dL | Injectafer | Normal Saline |
|---|---|---|
| Hepcidin in 1st Tertile | 0.88 ± 1.892 | 1.13 ± 1.203 |
| hepcidin in 3rd Tertile | 1.28 ± 1.552 | 0.02 ± 1.394 |
Summary of the actual value and change from baseline in total score of Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue Scale). Ranges from 0-52 and higher scores mean better Quality of Life (QOL). Data collected after receiving non-study intervention will not be included in the summary.
| Score on a scale | Injectafer | Normal Saline |
|---|---|---|
| Baseline | 21.8 ± 9.47 | 21.5 ± 8.64 |
| Day 7 Change from Baseline | -0.8 ± 6.78 | -0.7 ± 6.21 |
| Week 2 Change from Baseline | -0.3 ± 7.34 | 0.2 ± 8.13 |
| Week 3 Change from Baseline | -0.3 ± 7.75 | -0.6 ± 7.41 |
| Week 6 Change from Baseline | -0.2 ± 9.70 | -0.7 ± 8.13 |
| Week 9 Change from Baseline | -0.7 ± 8.35 | 0.3 ± 8.22 |
| Week 12 Change from Baseline | -0.1 ± 9.82 | -0.5 ± 8.09 |
| Week 15 Change from Baseline | -0.1 ± 9.65 | 0.8 ± 9.11 |
| Week 18 Change from Baseline | -1.5 ± 8.78 | 0.0 ± 8.92 |
Collected over 1 year, 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Injectafer | 0/121 (0%) | 28/121 (23.1%) | 96/121 (79.3%) |
| Normal Saline | 0/118 (0%) | 22/118 (18.6%) | 95/118 (80.5%) |
| Event | Injectafer | Normal Saline |
|---|---|---|
| Gastrointestinal DisordersGastrointestinal disorders | 7/121 | 0/118 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/121 | 1/118 |
| Respiratory, Thoracic and Mediastinal DisordersRespiratory, thoracic and mediastinal disorders | 5/121 | 3/118 |
| Disease progressionGeneral disorders | 4/121 | 4/118 |
| Blood And Lymphatic System DisordersBlood and lymphatic system disorders | 4/121 | 3/118 |
| Infections And InfestationsInfections and infestations | 4/121 | 3/118 |
| Cardiac DisordersCardiac disorders | 2/121 | 3/118 |
| Hepatobiliary DisordersHepatobiliary disorders | 0/121 | 3/118 |
| Renal And Urinary DisordersRenal and urinary disorders | 3/121 | 2/118 |
| Event | Injectafer | Normal Saline |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 21/121 | 14/118 |
| HypophosphatemiaMetabolism and nutrition disorders | 19/121 | 3/118 |
| FatigueGeneral disorders | 18/121 | 17/118 |
| Respiratory, Thoracic and Mediastinal DisordersRespiratory, thoracic and mediastinal disorders | 11/121 | 17/118 |
| Infections and InfestationsInfections and infestations | 16/121 | 14/118 |
| DiarrhoeaGastrointestinal disorders | 15/121 | 8/118 |
| LeukopeniaBlood and lymphatic system disorders | 15/121 | 13/118 |
| NauseaGastrointestinal disorders | 11/121 | 11/118 |
| AstheniaGeneral disorders | 10/121 | 11/118 |
| PyrexiaGeneral disorders | 6/121 | 11/118 |
| Age, Continuous(years) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Mean | 63.0 ± 10.02 | 63.1 ± 9.26 | 63.0 ± 9.63 |
| Sex: Female, Male(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Female | 67 | 69 | 136 |
| Male | 55 | 53 | 108 |
| Ethnicity (NIH/OMB)(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 7 | 10 |
| Not Hispanic or Latino | 119 | 115 | 234 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Race — White | 117 | 112 | 229 |
| Race — Black/African-American | 5 | 8 | 13 |
| Race — Multiple | 0 | 2 | 2 |
| Race — American Indian/Alaska Native | 0 | 0 | 0 |
| Race — Asian | 0 | 0 | 0 |
| Race — Native Hawaiian/Other Pacific Islander | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| United States | 22 | 22 | 44 |
| Georgia | 39 | 38 | 77 |
| Hungary | 26 | 27 | 53 |
| Poland | 24 | 24 | 48 |
| Bulgaria | 11 | 11 | 22 |
| Height(cm) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Mean | 166.9 ± 9.5 | 165.9 ± 9.6 | 166.4 ± 9.5 |
| Iron intolerance(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Yes | 3 | 3 | 6 |
| No | 119 | 119 | 238 |
| ECOG grade(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| 0 | 39 | 30 | 69 |
| 1 | 75 | 83 | 158 |
| 2 | 8 | 9 | 17 |
| 3 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from May 2015 to primary completion in Jan 2018, 32 months.
Results were first posted in May 2021, 3 years 4 months after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 32 months is below that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose